Japanese pharmaceutical giant Takeda Pharmaceutical announced its strategic decision to discontinue all cell therapy research and seek external partnerships to advance existing clinic-ready cell therapy programs. This shift ends its foray into the modality, despite previous investments and manufacturing capability build-outs. Takeda plans to redirect resources towards small molecules, biologics, and antibody-drug conjugates that promise transformative therapies with faster clinical impact. The move includes an impairment charge of approximately $394 million related to its gamma delta cell therapy technology. The decision reflects industry trends amid funding challenges for cell therapies.